NCT05723107
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Halted prematurely Show 5 more changesShow less
- Eligibility criteria expanded, about 8 words
- Final enrollment: 6 participants (planned 15)
- Primary completion date changed from estimate of Nov 2027 to Nov 25, 2024
- Study completion date changed from estimate of Mar 2028 to Feb 25, 2025
- Site details revised
- Notable Primary completion date: Nov 2026 to Nov 2027
- Study completion date: Mar 2027 to Mar 2028
- Notable Primary completion date: Nov 2025 to Nov 2026
- Study completion date: Mar 2026 to Mar 2027
- Minor Start date: Mar 20, 2023 to Mar 31, 2023v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Mar 2023 to Mar 20, 2023
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and chemotherapy will be administered as part of standard of care treatment for PDAC in patients receiving palliative second- or third-line therapy for unresectable non-metastatic pancreatic cancer. Study participants will undergo 3 identical EUS-RFA procedures, administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), and Window 4 (Weeks 9-11). During each EUS-RFA procedure, a tumor biopsy will also be taken for single cell RNA sequencing. Chemotherapy will be administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), Window 4 (Weeks 9-11), and Window 5 (Weeks 13-15).
Drugs: Chemotherapy
Devices: Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)
Sites
1 site in 1 country
- Tisch HospitalNew York, New York, United States